{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:19:28Z","timestamp":1789006768733,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01209-w","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T05:01:50Z","timestamp":1718773310000},"page":"1875-1890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Sof\u00eda","family":"Haselgruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fern\u00e1ndez-Crehuet-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Fern\u00e1ndez-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Padial-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ortiz-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Navarro-Guillam\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Membrive-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cuenca-Barrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"1209_CR1","unstructured":"Cosentyx | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx. Accessed 10 Mar 2024."},{"issue":"5","key":"1209_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525\u201345.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/jdv.17351","volume":"35","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797\u2013810.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1209_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, et al. Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ad.2022.12.005","volume":"115","author":"FJ Melgosa Ramos","year":"2024","unstructured":"Melgosa Ramos FJ, Garc\u00eda-Ruiz R, Mateu Puchades A, Martorell A. Can we improve prognosis in hidradenitis suppurativa? identifying patients in the window of opportunity. Actas Dermosifiliogr. 2024;115(2):213\u20134.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"1209_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase\u00a02 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1209_CR7","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1209_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2023","unstructured":"Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37(2):395\u2013401.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1209_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s13555-023-00906-2","volume":"13","author":"P Fernandez-Crehuet","year":"2023","unstructured":"Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A, et al. Short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study. Dermatol Ther (Heidelb). 2023;13(4):1029\u201338.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10378","key":"1209_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week\u00a016 and week\u00a052 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase\u00a03 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"issue":"3","key":"1209_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.17822","volume":"181","author":"L Prussick","year":"2019","unstructured":"Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609\u201311.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1209_CR13","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","volume":"82","author":"RG Casseres","year":"2020","unstructured":"Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1209_CR14","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1111\/jdv.16605","volume":"34","author":"Z Reguia\u00ef","year":"2020","unstructured":"Reguia\u00ef Z, Fougerousse AC, Maccari F, B\u00e9cherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):e750\u20131.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1209_CR15","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1111\/jdv.17178","volume":"35","author":"S Ribero","year":"2021","unstructured":"Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1209_CR16","doi-asserted-by":"publisher","first-page":"T360","DOI":"10.1016\/j.ad.2022.03.037","volume":"114","author":"FJ Melgosa Ramos","year":"2023","unstructured":"Melgosa Ramos FJ, Garc\u00eda-Ruiz R, Geg\u00fandez Hern\u00e1ndez H, Mateu-Puchades A. Real-life experience of secukinumab in patients with hidradenitis suppurativa. Actas Dermosifiliogr. 2023;114(4):T360\u20132.","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"1209_CR17","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1111\/jdv.18685","volume":"37","author":"FJ Melgosa Ramos","year":"2023","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Est\u00e9banez Corrales A, Mateu PA. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. 2023;37(4):e517\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1209_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CCID.S449367","volume":"17","author":"F Martora","year":"2024","unstructured":"Martora F, Marasca C, Cacciapuoti S, et al. Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study. Clin Cosmet Investig Dermatol. 2024;17:159\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1209_CR19","first-page":"042","volume":"2","author":"HC Ring","year":"2024","unstructured":"Ring HC, Thorsen J, Kirby B, et al. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study. Br J Dermatol. 2024;2:042.","journal-title":"Br J Dermatol"},{"key":"1209_CR20","doi-asserted-by":"publisher","DOI":"10.1159\/000535867","author":"HH van der Zee","year":"2023","unstructured":"van der Zee HH, van Huijstee JC, van Straalen KR, et al. Viewpoint on the evaluation of severity and treatment effects in mild hidradenitis suppurativa: the cumulative IHS4 (IHS4-C). Dermatology. 2023. https:\/\/doi.org\/10.1159\/000535867.","journal-title":"Dermatology"},{"issue":"1","key":"1209_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bjd.19165","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC. First real-world data provide evidence for a \u2018window of opportunity\u2019 in treatment of hidradenitis suppurativa\/acne inversa. Br J Dermatol. 2021;184(1):10\u20131.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1209_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41391-021-00328-1","volume":"24","author":"DE Spratt","year":"2021","unstructured":"Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):647\u201361.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"1209_CR23","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1093\/rheumatology\/keaa860","volume":"60","author":"NMT Roodenrijs","year":"2021","unstructured":"Roodenrijs NMT, van der Goes MC, Welsing PMJ, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford). 2021;60(8):3778\u201388.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1209_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/jdv.19725","volume":"38","author":"P Aarts","year":"2024","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Straalen KR, Prens EP. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024;38(5):904\u20139.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01209-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T13:18:00Z","timestamp":1721481480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01209-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01209-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sofia Haselgruber declares no conflict of interest. Pablo Fernandez-Crehuet-Serrano declares no conflict of interest. Maria Dolores Fernandez-Ballesteros declares no conflict of interest. Alicia Padial-Gomez declares no conflict of interest. Juan Carlos Hernandez-Rodriguez declares no conflict of interest. Juan Ortiz-Alvarez declares no conflict of interest. Pedro Navarro-Guillamon declares no conflict of interest. Cristina Membrive-Jimenez declares no conflict of interest. Carlos Cuenca-Barrales declares no conflict of interest. Alejandro Molina-Leyva is an Editorial Board member of<i> Dermatology and Therapy<\/i>. Alejandro Molina-Leyva was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the local ethics committee. All participants provided informed consent before their inclusion in the study, and measures were taken to ensure confidentiality and anonymity of their personal information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}